Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEpe Special Opp Regulatory News (ESO)

Share Price Information for Epe Special Opp (ESO)

Share Price is delayed by 15 minutes
Get Live Data
235.00    0.00 (0.00%)
Bid:
232.00
Ask:
238.00
Spread: 6.00 (2.586%)
Market Cap: £57.44m
ESO Live PriceLast checked at - London Stock Exchange

Intraday Epe Special Opp Share Chart

Portfolio Update

29 Mar 2018 07:00

RNS Number : 3283J
EPE Special Opportunities PLC
29 March 2018
 

EPE Special Opportunities plc

29 March 2018

 

This announcement contains inside information

 

EPE Special Opportunities plcPortfolio Update

EPE Special Opportunities plc ("ESO plc", or the "Company") announces that Pharmacy2U Limited ("P2U"), a company in which it has a minority investment via ESO Investments 1 LP ("ESO 1 LP"), has raised a further £40 million of new growth capital to support the rapid expansion of its online NHS repeat prescription service.

P2U is England's leading online NHS pharmacy and is the fastest growing pharmacy group in the country, with 25,000 new patient registrations in the last month alone and year-on-year growth in patient numbers of 178%.

As well as offering consumers increased choice and convenience, P2U's online prescription management service is highly beneficial for the healthcare economy, saving GPs an estimated six hours and 40 minutes a week on paperwork. It is estimated that managing repeat prescriptions online could save the NHS over £300 million per year on prescription costs.

The growth capital raise was led by G Square Capital, a European private equity firm focussed on the healthcare sector. In conjunction with the new investment, G Square Capital also acquired a majority of the share capital of P2U from existing shareholders and as a result is now the majority shareholder.

The new investment will allow P2U to invest further in technology infrastructure to support customer demand and remain at the forefront of innovation in digital pharmacy services. P2U's state-of-the-art, award winning dispensing facility in Leeds is already the largest and most technologically advanced in the United Kingdom, with the ability to dispense one million prescription items per month.

ESO 1 LP has realised 50% of its existing investment in P2U in the transaction, implying a 2.0x Money Multiple realised return. The transaction was completed at a premium to the holding value of P2U. The remaining 50% of ESO 1 LP's investment has been retained to benefit from the growth potential in P2U offered by the £40 million investment. This retained investment offers further upside in terms of Money Multiple returns to ESO 1 LP

The person responsible for releasing this information on behalf of the Company is Hilary Jones of R&H Fund Services (Jersey) Limited.

 

Enquiries:

 

EPIC Private Equity LLP

+44 (0) 207 269 8865

Alex Leslie

R&H Fund Services (Jersey) Limited

+44 (0) 1534 825 323

Hilary Jones

Cardew Group Limited

+44 (0) 207 930 0777

Richard Spiegelberg

Numis Securities Limited

+44 (0) 207 260 1000

Nominated Advisor:

Stuart Skinner / Hugh Jonathan

Corporate Broker:

Charles Farquhar

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PFUDBGDXXBDBGII
Date   Source Headline
9th Apr 20247:00 amRNSVesting - Share Matching Scheme/PDMR Shareholdings
9th Apr 20247:00 amRNSPosting of Report & Accounts
2nd Apr 20247:00 amRNSHolding(s) in Company
28th Mar 20247:00 amRNSAnnual Financial Report
5th Mar 20247:00 amRNSHolding(s) in Company
13th Feb 20246:00 pmRNSDirector/PDMR Shareholding
8th Feb 20244:45 pmRNSTrading Update
8th Feb 20247:00 amRNSInterest Payment on Unsecured Loan Notes
10th Jan 20247:00 amRNSNet Asset Value(s)
20th Dec 20237:00 amRNSHolding(s) in Company
20th Dec 20237:00 amRNSHolding(s) in Company
14th Dec 20237:00 amRNSNet Asset Value(s)
9th Nov 20237:00 amRNSNet Asset Value(s)
26th Oct 20236:29 pmRNSDirector/PDMR Shareholding
17th Oct 20236:30 pmRNSHolding(s) in Company
10th Oct 20234:30 pmRNSNet Asset Value(s)
3rd Oct 20236:00 pmRNSDirector Retirement
20th Sep 20237:00 amRNSDirector/PDMR Shareholding
15th Sep 20237:00 amRNSHalf-year Report
4th Sep 20235:00 pmRNSHolding(s) in Company
1st Aug 20237:00 amRNSHolding(s) in Company
1st Aug 20237:00 amRNSInterest Payment on Unsecured Loan Notes
26th Jul 20237:00 amRNSUpdate on Share Buy Backs
24th Jul 20237:00 amRNSTransaction in Own Shares
24th Jul 20237:00 amRNSExtension of Unsecured Loan Notes
21st Jul 20237:00 amRNSTransaction in Own Shares
19th Jul 20239:30 amRNSAnnouncement of ZDP Share Buybacks
18th Jul 202310:00 amRNSPortfolio Update
11th Jul 20237:00 amRNSNet Asset Value(s)
30th Jun 20237:01 amRNSProposed Extension of Unsecured Loan Notes
30th Jun 20237:00 amRNSResult of AGM
12th Jun 20237:00 amRNSNet Asset Value(s)
19th May 20237:00 amRNSNotice of AGM
17th May 20237:00 amRNSPosting of Annual Report and Accounts
12th May 20237:00 amRNSHolding(s) in Company
12th May 20237:00 amRNSVesting - Share Matching Scheme/PDMR Shareholdings
12th May 20237:00 amRNSDirector/PDMR Shareholding
11th May 20237:00 amRNSNet Asset Value(s)
20th Apr 20237:00 amRNSHolding(s) in Company
18th Apr 20237:00 amRNSTransaction in Own Shares
13th Apr 20237:00 amRNSDirector/PDMR Shareholding
11th Apr 20237:00 amRNSNet Asset Value(s)
21st Mar 20237:04 amRNSAnnual Financial Report
21st Mar 20237:00 amRNSAnnual Financial Report
6th Feb 20237:00 amRNSTrading Update
6th Feb 20237:00 amRNSTrading Update
3rd Feb 20237:00 amRNSInterest Payment on Unsecured Loan Notes
11th Jan 20237:00 amRNSNet Asset Value(s)
20th Dec 20225:00 pmRNSHolding(s) in Company
15th Dec 20227:00 amRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.